Trial Profile
A Phase IIa Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Efficacy of EIDD-2801 to Eliminate SARS-CoV-2RNA Detection in Persons With COVID-19
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 May 2022
Price :
$35
*
At a glance
- Drugs Molnupiravir (Primary)
- Indications SARS-CoV-2 acute respiratory disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Ridgeback Biotherapeutics
- 23 Nov 2021 Results assessing the comprehensive analysis of demographic, immunologic, virologic, and clinical disease factors associated with infectious virus isolation and levels of viral RNA in nasopharyngeal swab samples in the largest study of symptomatic outpatient adults with COVID-19, published in the Clinical Infectious Diseases.
- 10 Mar 2021 Results presented at the 28th Conference on Retroviruses and Opportunistic Infections
- 06 Mar 2021 According to a Merck media release, findings from the primary efficacy and safety endpoints and additional secondary objectives will be presented at an upcoming medical meeting.